Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06273306

Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)

The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up.

This is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis with Rheumatoid Arthritis or Spondylarthritis
  • Treatment with biologic or targeted disease modifying antirheumatic drugs.
  • Ability to use smartphone.

Exclusion criteria

  • only patients with conditions that hinder or prevent the use of a mobile application (blindness, mental retardation, dementia, digitalfilliteracy).

Treatment and study plan

IMIDOC

Device

Patient´s Mobile App for recording clinical data

Primary outcomes

  1. To assess the primary objective, composite endpoints that consider the viability, adherence and degree of satisfaction of the MAM are included

    Time frame: 24 months

    • Number of interactions in activity and electronic patient reported outcomes (ePRO) questionnaires per month.
    • Number of reported incidences per month.
    • Average time to contact the patient after reporting an incident.
    • Average number of interactions in educational material and other content per month.
    • Adherence to follow-up through the mixed atenttion model (MAM) will be evaluated through the number of visits and time per visit to the digital platform.
    • Percentage of incidents resolved telematically.
    • Average weekly hours that the digital clinician takes to review the professional's website and resolve incidents
    • Professionals and patients´ satisfaction will be assessed through the Net-Promoter-Score (NPS). Values from 0 to 6 ( detractors), 6-8 ( passives) and 9-10 promoters.

Secondary outcomes

  1. To identify features associated with adherence to follow-up through the MAM.

    Time frame: 24 months

    • A 22-item self-administered survey adapted from the Unified Theory of Acceptance and Use of Technology (UTAUT) model will be used to measure app acceptance and intention to use: the variables will measured with 7-point scales for all model components as in the original UTAUT, where 1 equalled the negative end (fully disagree) and 7 the positive end of the scale (fully agree).
    • Agreement between patients' self-assessment and clinician assessment will be assessed comparing face-to-face visits at 6-months intervals with the closest assessment in the digital solution.
    • Number of face-to-face visits are avoided with the mixed atenttion model (MAM) in patients with stable disease activity.
    • Patients' eHealth literacy will be measured using the validated Spanish version of the eHealth Literacy Scale (eHEALS), measured on a 5-point scale in the range from 1 (strongly disagree) to 5 (strongly agree)

Study contacts

Contact information is provided by the study sponsor or research team.

Chamaida Plasencia-Rodríguez, PhD

CONTACT

[email protected]

917277108

Sponsors and collaborators

Lead sponsor

Instituto de Investigación Hospital Universitario La Paz

Other

Registry information

Official study title

Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model

Acronym: IMIDOC

Important dates

Study start
2024
Primary completion
2024
Study completion
2026
First posted
Feb 22, 2024
Registry last updated
Feb 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.